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ABSTRACT 
Matrix metalloproteinases (MMPs) are matrix-degrading enzymes that are over-expressed in joints of rheumato- 
id arthritis (RA) patients. However, the contribution of specific MMPs for the development of arthritic joints is 
unknown. This study is aimed at studying the role of matrix metalloproteinase-9 (MMP-9) in mice, using the 
K/BxN serum-transfer model of RA. Arthritis was induced in Balb/c mice by injecting K/BxN serum. Develop-
ment of arthritis was followed in these mice by measuring ankle thickness and clinical index score. MMP-9 ex-
pression in the joints of mice killed at various time points during the disease progression was determined by ge-
latin zymography using ankle lysates. We found that MMP-9 expression increased with the severity of arthritis. 
Importantly MMP-9 deficient mice injected with K/BxN serum showed a milder form of arthritis in comparison 
to the control C57BL/6 mice injected with K/BxN serum. We therefore conclude that MMP-9 promotes arthritis 
in mice. 
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1. Introduction 
Rheumatoid arthritis (RA) is a chronic, inflammatory, 
autoimmune disease that primarily affects the synovial 
joints and leads to impairment of physical activity and 
quality of life in patients [1-3]. The inflamed joint in RA 
produces proteases responsible for the degradation of the 
extracellular matrix (ECM) and distortion of the archi- 
tecture and function of the joints [4]. Of the proteases, 
MMP-1, -8 and -13 are collagenases and are therefore 
involved in the breakdown of collagen. The cleaved col-
lagen is further degraded by another class of MMPs, the 
gelatinases MMP-9 and MMP-2 [4]. The proteolytic ac-
tivity of MMPs is tightly controlled by their interaction 
with endogenous tissue inhibitors of matrix metallopro-
teinases (TIMPs), which specifically inhibit the active 
form of MMPs [5-7]. The balance between MMPs and 
TIMPs plays an important role in maintaining tissue inte- 
grity [7]. For example, MMP-3 cleaves MMP-9 and ac-
tivates it, however, when TIMP-1 binds to pro-MMP-9 it 
protects MMP-9 from MMP-3 cleavage [8].  
In joints of rheumatoid arthritis patients, MMPs break 
down the matrix elements and allow inflammatory cells 
to migrate into the site of inflammation inducing long- 
term irreversible damage [9-11]. Among the MMPs, 
MMP-9 is important as it can degrade denatured collagen, 
gelatin as well as other ECM components [12,13]. Both 
the invading immune cells as well the resident cells of 
the synovial joints secrete MMP-9 and in combination 
with other MMPs degrade all the components of the extra 
cellular matrix [10,14-16]. There is now significant evi- 
dence for the over expression of MMP-9 in tissues de- 
rived from patients with arthritic disease [16-18]. Animal 
models of RA are useful in understanding the pathogene- 
sis of RA. Therefore, studying MMP-9 expression during *Corresponding author. 
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disease progression in animal models of RA will give a 
better understanding of the role of this protease in arthri- 
tis [19].  
The K/BxN serum transfer arthritis model is one such 
model that shares features similar to human RA [20]. The 
K/BxN mice are a cross between the KRN mice and the 
NOD mice strain. The KRN mice carry the transgenic T 
cell receptor (TCR) on the CD4+ T cells that recognizes 
the glucose-6-phosphate isomerase (GPI) peptide bound 
to the NOD MHC II I-Ag7 [21]. KRN x NOD F1 mice 
show severe distal joint inflammation which onsets at 
about 4 - 5 weeks of age. The severe symmetrical po-
lyarthritis in these mice is dependent on the expression of 
the KRN TCR, and T cell help for B cells that make pa-
thogenic anti-GPI antibodies [21,22]. Importantly, serum 
or purified antibodies from the K/BxN mice cause arthri-
tis when transferred into various mouse strains [23,24]. 
The anti-GPI antibodies form immune complexes with 
GPI, triggering a joint-specific inflammatory response 
mediated by mast cells, neutrophils, macrophages, NK 
cells and Th17 cells [22,24-29]. The arthritis induced in 
mice by transfer of K/BxN serum is independent of the T 
and B cell mediated autoimmune phase and has a pre-
dictable onset, since the same quantity of antibodies is 
injected into the mice. These features distinguish the 
K/BxN serum transfer model from other models of arth-
ritis. It is a valuable tool in investigating factors contri-
buting to inflammation, bone and cartilage destruction 
during arthritis that develop independent of the autoim-
mune phase of the disease [20,30]. In this study we have 
used the K/BxN serum-transfer model to investigate the 
role of MMP-9 in arthritis progression in mice. 
2. Materials and Methods 
2.1. Experimental Animals 
MMP-9−/− mice were a kind gift from Dr. Steven D Sha- 
piro. C57BL/6 mice used as WT control for MMP-9−/− 
mice and Balb/c mice were maintained and bred at the 
animal facility of the University of Konstanz. Animal 
experimentation was according to the local laws and with 
permission of the ethical committee (Table 1). 
2.2. Induction of Arthritis by K/BxN Serum  
Transfer and Assessment of Arthritis 
As previously described, K/BxN mice were generated by 
crossing the KRN mice with the NOD mice [31,32]. Se- 
rum collected from the arthritic K/BxN mice was pooled 
and arthritis was induced in the recipient mice by an 
intraperitoneal injection of 200 µl of K/BxN serum. In- 
crease in ankle thickening was monitored using a mi- 
crometer (Hann & Kolb-model no 33185). Ankle thick- 
ness was measured till day 14 post serum-transfer. Ankle 
thickness expressed in millimeters (mm) is the average 
measured in all four legs recorded on a particular day 
post serum-transfer. Clinical index score was measured 
in a scale varying from 0 to 4. The lowest score of 0 was 
given for a leg when it had no signs of swelling and a 
score of 1 additively for each leg when it has a developed 
swelling. The macroscopic score was expressed as the 
sum of scores of all the four legs. 
2.3. Gelatin Zymography 
Gelatin zymography was conducted using ankle homo- 
genates from mice. Mice were sacrificed by cervical dis- 
location. Whole mouse ankles were removed and homo- 
genized in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 
1% Nonidet P-40 and centrifuged at 15,000 rpm for 10 
min. The protein concentration of the supernatant was 
determined and Novex precast gelatin gel (10% tris- 
Glycine gel with 0.1% gelatin) was loaded with lysates 
of equal protein concentration. Electrophoresis was per- 
formed using Novex mini-cell electrophoresis system 
(Invitrogen, Germany) under constant voltage of 125 V 
for 2 hrs at 4˚C. After electophoresis, the gel was incu- 
bated in Novex zymogram renaturing buffer with gentle 
agitation for 30 min at room temperature. The zymogram 
renaturing buffer was then replaced with the zymogram 
developing buffer and incubated at room temperature for 
30 min. In the next step the zymogram developing buffer 
was replaced with fresh buffer and incubated at 37˚C 
over night. The gel was then stained with Coomassie 
Blue R-250 at a concentration of 0.5% (w/v) for 30 min.  
 
Table 1. List of mouse strains used. 
Strain Characteristics Usage 
C57BL/6 
Commonly used inbred  
strain of mice. 
Used as wild type  
control for  
MMP-9−/− mice 
MMP-9−/− 
Mice are homozygous  
null for MMP9 gene. 
Used to asses role  
of MMP-9 in K/BxN 
serum induced arthritis. 
KRN 
Mice carrying the transgenic  
T cell receptor that  
recognizes GPI. 
Crossed with NOD  
to produce the  
K/BxN mice. 
NOD Non-obese diabetic mice. 
Crossed with the  
KRN to produce the 
K/BxN mice. 
K/BxN 
Mice obtained by crossing the 
KRN mice with NOD. The 
K/BxN develop arthritis around 4 
weeks of age. 
Serum collected  
from the arthritic 
K/BxN mice used  
to induce arthritis  
in susceptible mice. 
Balb/c 
Commonly used inbred strain  
of mice. Susceptible to K/BxN 
serum induced arthritis. 
Used to assess the  
expression of MMP-9 in 
the joints during  
K/BxN serum  
induced arthritis. 
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The gel was subsequently destained with destaining solu- 
tion. Still areas of protease activity appeared as clear 
bands. Prestained standard (6 to 206 kDa) protein marker 
(BioRAD, Germany) was used to determine the molecu- 
lar weight of the gelatinases. Gels were laminated and 
scanned using BioRad Molecular Imager Fx. The inten- 
sity of bands in zymography was quantified using Bio- 
Rad Quantity One software. 
2.4. Statistical Analysis 
The groups were compared using the two-tailed unpaired 
student t test. Prism software (version 5; GraphPad Soft- 
ware) was used for statistical analysis. 
3. Results 
3.1. Expression of MMP-9 Increases in Parallel  
to Progression of K/BxN Serum Induced  
Arthritis 
To investigate the role of MMP-9, we analyzed the ex- 
pression of MMP-9 in the ankle joints of mice following 
a single injection of K/BxN serum for 14 days in Balb/c 
mice. To evaluate the progress of arthritis we recorded 
the ankle thickness and clinical index score of Balb/c 
mice injected with K/BxN serum (Figures 1(a) and (b)). 
Arthritis manifested in the mice around day 2, and 
peaked around day 6 and subsequently resolved by day 
14. Mice were sacrificed on days 0, 3, 6, 10, 14 and 19 
after serum-transfer for analysis by zymography. Ankle 
joints were removed and lysates were prepared and ex-
amined for MMP-9 gelatinolytic activity by gelatin zy-
mography (Figure 1(c)). The expression of MMP-9 at 
different time points was quantified by densitometry on 
the zymograms. Densitometric measurement revealed 
that the gelatinolytic activity of MMP-9 increased with 
the progress of the disease (Figure 1(d)). There was an 
increase in expression of MMP-9 on day 1 with a maxi-
mum expression being observed on day 6. Thereafter, the 
expression of MMP-9 decreased until day 14 in parallel 
with the resolving arthritis. Thus, there is an increase in 
MMP-9 expression in the joints of the mice with the pro-
gression of arthritis after K/BxN serum-transfer. 
3.2. MMP-9−/− Mice Exhibit Reduced Arthritis 
Now, that we found an increased expression of MMP-9 
during antibody-induced arthritis in the joints, we inves- 
tigated whether deficiency of MMP-9 could possibly 
reduce arthritis. We addressed this by inducing arthritis 
in the MMP-9 deficient mice (MMP-9−/−) and the wild 
type controls (C57BL/6), by injecting 200 µl of K/BxN 
serum. Ankle thickness and clinical index score were 
recorded as given in the materials and methods. A sig-
nificant reduction in arthritis was observed in the 
MMP-9−/− mice when compared to C57BL/6 mice 
(Figures 2(a) and (b)). On day 7, the ankle thickness 
score was reduced over 50% in the MMP-9−/− mice when 
compared to the C57BL/6 mice (P > 0.0025) (Figure 
2(a)). A decrease in the clinical index score was also 
observed, with a maximum of 1.8 ± 0.58 in the 
MMP-9−/− mice compared to a maximum of 3.6 ± 0.24 in 
the C57BL/6 on day 7 (Figure 2(b)). Thus, MMP-9−/− 
mice showed a milder arthritis than the C57BL/6 mice. 
4. Discussion 
The data presented here, demonstrate a significant role 
for MMP-9 in the K/BxN serum-induced arthritis. We 
found that MMP-9 is over expressed upon induction of 
arthritis by serum-transfer. The increase in MMP-9 ex- 
pression occurs on day 1 even before any clinical ma- 
nifestation of arthritis implying that the secretion of 
MMP-9 in the synovial joints may be required for the 
initiation of arthritis. In these mice the expression of 
MMP-9 then increases with the progression of arthritis 
and reaches maximum levels around day 6 which coin- 
cides with the appearance of maximal ankle thickness. 
We have shown here that in K/BxN serum induced arth- 
ritis the expression of MMP-9 simultaneously increases 
along with ankle thickness during disease progression. 
The requirement of MMP-9 for arthritis was further 
demonstrated by the reduced severity of arthritis in the 
MMP-9−/− mice injected with K/BxN serum. The 
MMP-9−/− mice showed more than 50% reduction in an-
kle thickness when compared to the C57BL/6 mice. The 
lack of complete protection against arthritis indicates a 
role for other MMP-s like MMP-13 [33] or MMP-2 that 
could compensate for the absence of MMP-9 in these 
mice. A similar role for MMP-9 in promoting arthritis 
was demonstrated in the collagen antibody induced mod-
el of arthritis [34]. Here, the authors demonstrated that 
there is an increased expression of MMP-9 during colla-
gen antibody induced arthritis and MMP-9−/− mice showed 
reduced levels of antibody induced arthritis indicating 
that MMP-9 is required for the development of antibody 
induced arthritis in this model too. 
Arthritis in the K/BxN serum-transfer model is me- 
diated by immunecomplexes that localize in the joints 
within few hours following injection of K/BxN serum 
[35]. This rapid accumulation of immune complexes is 
due to an increased vascular permeability of the joints 
that is mediated by cytokines like TNF-α secreted by 
activated neutrophils in the blood [36,37]. Neutrophils 
and other cell types like macrophages, mast cells and NK 
cells in the joint are further activated by GPI antibodies 
bound to the GPI on the articular cartilage surface [36] 
through Fc receptors [23]. This results in the production 
of proinflammatory cytokines like TNF-α, IL-1 [38] and 
chemokines like macrophage inflammatory protein-   
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Figure 1. Increased expression of MMP-9 is observed during the development of K/BxN serum induced arthritis. Average 
ankle thickness measurements (a) and clinical index scores (b) of Balb/c mice (n = 5; ± SEM) injected with 200 µl of K/BxN 
serum. Data are a representative of >3 experiments. (c) MMP-9 expression in the ankles of mice injected with K/BxN serum. 
Lysates of the ankles of mice sacrificed on day 0 (before serum transfer), and on days 1, 3, 6, 10, 14, and 19 days post K/BxN 
serum injection were analyzed by gelatin zymography. (d) The expression of MMP-9 in the zymogram was quantified by 
densitometry. Bars in the graph represent the fold difference of the density of the MMP-9 band over the background of the 
gel given an arbitrary unit of 1. Data is in c & d representative of two experiments. 
 
 
 
Figure 2. MMP-9−/− mice are partially protected from 
K/BxN serum induced arthritis. Average ankle thickness 
measurements ±SEM (a) and clinical index scores ± SEM (b) 
of MMP-9−/− mice (n = 5) and C57BL/6 mice (n = 5) injected 
with 200µl of K/BxN serum; **P < 0.0025. Data are a repre- 
sentative of two experiments. 
1α [39] that trigger a strong inflammatory response in 
the joints. Neutrophils thus play a predominant role in 
initiation and progression of K/BxN serum-transfer arth- 
ritis [26]. Apart from inflammatory cytokines, activated 
neutrophils have been shown to secrete MMP-9 as well, 
implicating them as the possible source of MMP-9 
[10,14,40]. Other than neutrophils, MMP-9 is secreted by 
other cell types like the synovial fibroblasts, macro- 
phages and endothelial cells [10,41]. MMP-9 promotes 
arthritis by degrading the extracellular matrix surround- 
ing the joints, degrading anti-inflammatory factors or 
activating inflammatory factors [42]. MMP-9 has been 
found to be required for osteoclasts migration in vitro [43] 
and for osteolcast mediated angiogenesis during bone 
remodeling [44]. Future investigations using the K/BxN 
serum transfer model need to be performed to define the 
cell type specific effect of MMP-9 deficiency and the 
mechanisms of MMP-9 activity in arthritic mice. Such 
studies will lead to identifying novel inhibitors of MMP- 
9 as therapeutic agents in the treatment of RA. 
Thus, in this study we demonstrate that MMP-9 is re- 
quired for the development of K/BxN serum-induced 
arthritis. The K/BxN serum-transfer model could be fur- 
ther used to investigate the mechanisms by which MMP- 
9 promotes inflammation in RA and to test inhibitors of 
MMP-9 like TIMP-1 as therapeutic options in the treat- 
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ment of RA. 
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